 |
 |
 |
|
|
 |
| EXECUTIVE BIOS |
 |
Bruce L.A. Carter, Ph.D.
Chairman of the Board
Chief Executive Officer
Dr. Carter was appointed Chairman of the Board in April 2005. Dr. Carter has been ZymoGenetics' Chief Executive Officer since April 1998. Dr. Carter first joined ZymoGenetics in 1986 as Vice President of Research and Development. In 1994, he was chosen as Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk A/S, the former parent company of ZymoGenetics. He was elected to the board of ZymoGenetics in 1987 and was appointed president of the company in 1998. Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk in 2000. Dr. Carter held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.
|
 |
Michael J. Dwyer
Senior Vice President,
Sales and Marketing
Mike Dwyer joined ZymoGenetics in May 2006 as Senior Vice President of Marketing and Sales. Mr. Dwyer has nearly thirty years experience in biologic and pharmaceutical marketing and sales. He is responsible for ZymoGenetics sales, marketing and operations/logistics team. Prior to ZymoGenetics, Mr. Dwyer served as Vice President, Diabetes Sales for Novo Nordisk, where he was responsible for planning and implementing selling strategies, designing launch strategies and operations and recruiting sales forces for the U.S. launch of NovoSeven® and Norditropin®. Mr. Dwyer has held positions in marketing and sales at Bayer/Miles Inc. where he assisted in developing the introductory strategy and product launch for Kogenate® (recombinant Factor VIII). Mr. Dwyer also served as Vice President of Marketing and Materials Management for Caremark Therapeutic Services, a biopharmaceutical provider of home therapies and services. Mr. Dwyer holds an M.B.A. from Pepperdine University and a B.S. from University of Dayton. |
 |
Heather L. Franklin
Senior Vice President, Business Development
Heather L. Franklin was named Senior Vice President, Business Development in June, 2008. Prior to that, she was Vice President, Business Development from January 2005 to June 2008, Senior Director, Strategic Alliance Management from July 2003 to January 2005 and Director, Strategic Alliance Management from January 2002 to July 2003. In these roles she was instrumental in negotiating and managing major partnerships with Novo Nordisk, Merck Serono and Bayer. Ms. Franklin joined ZymoGenetics in January, 2001 as Director, Research Project Management to establish a research project management system after holding roles of increasing responsibility in clinical and research project management at Amgen and Targeted Genetics from 1994 to 2001. She started her career in research roles at Seattle Biomedical Research Institute and Targeted Genetics. Ms. Franklin received a B.S. from the University of North Carolina, Chapel Hill, M.S. from the University of Washington and an M.B.A from the Wharton School of the University of Pennsylvania. |
 |
Darren R. Hamby
Senior Vice President, Human Resources
Darren Hamby was appointed Senior Vice President, Human Resources in July 2007. Previously, Mr. Hamby served as Vice President, Human Resources from August 2004 to June 2007, Senior Director, Human Resources from September 2002 to July 2004, and Director, Human Resources from July 2000 to August 2002. Mr. Hamby joined ZymoGenetics in September 1997 to manage compensation and employee benefit programs. From 1987 to 1997, Mr. Hamby held human resources positions of increasing responsibility with the Federal Home Loan Bank of Seattle. Mr. Hamby earned a Bachelor of Business Administration degree, with an emphasis in human resources management, and an M.B.A. from Pacific Lutheran University.
|
 |
Vaughn B. Himes, Ph.D.
Senior Vice President, Technical Operations
Dr. Himes was appointed Senior Vice President,
Technical Operations in May 2006. Dr.
Himes joined ZymoGenetics in November
2005 as Vice President, Commercial Manufacturing
Operations. Previously, Dr. Himes served
as Vice President for Worldwide Manufacturing
Operations for Corixa Corporation with
responsibility for manufacturing operations,
process development and quality control
in support of commercial and clinical
supplies. From 2000 to 2003, Dr.
Himes served as Vice President, Manufacturing
Operations for Targeted Genetics Corporation,
where he was responsible for manufacturing
and clinical supply operations for gene
delivery products. From 1999 to 2000,
Dr. Himes served as Vice President Product
Development for Genovo, Inc. Prior to
that, Dr. Himes held positions of increasing
responsibility over ten years with Wyeth-Lederle
Vaccines, including Associate Director
of Biological Development, Manager of
Viral Vaccine Development and Clinical
Production, and Cell Culture Pilot Plant
Supervisor. Dr. Himes received a Bachelors
of Arts in Chemistry from Pomona College
in California and a Ph.D. in Chemical
Engineering from the University of Minnesota. |
 |
James A. Johnson
Executive Vice President, Chief Financial Officer
and Treasurer
Mr. Johnson joined ZymoGenetics in February
2001 as Senior Vice President, Chief Financial
Officer and Treasurer, bringing over 20
years of financial experience to the company.
Prior to joining ZymoGenetics, he held numerous
positions at Targeted Genetics Corporation,
most recently as Senior Vice President and
Chief Financial Officer, where he led private
and public offerings, as well as establishing
a joint venture program to advance the company's
technology platforms. Other previous positions
include Vice President of Finance at Immunex
Corporation, Vice President and Controller
at Safeco Properties, Inc., and Senior Auditor
at Arthur Young. Mr. Johnson received a
B.A. in Business Administration from the
University of Washington. |
| |
|
 |
Nicole Onetto, M.D.
Senior Vice President and Chief Medical Officer
Dr. Nicole Onetto joined ZymoGenetics as Senior Vice President and Chief Medical Officer in September 2005. Dr. Onetto has over fifteen years of clinical drug development experience at leading biotechnology and pharmaceutical companies. Previously, Dr. Onetto was Executive Vice President and Chief Medical Officer at OSI Pharmaceuticals, where she headed the Development Organization and led the registration program for Tarceva (TM). Prior to that, Dr. Onetto served as Senior Vice President of Medical Affairs at Gilead Sciences and was also Senior Executive at Bristol-Myers Squibb in the oncology organization. While at BMS, she was the International Project Leader for Taxol. She also held clinical research positions of increasing responsibility at NeXstar Pharmaceuticals, Immunex and Hoechst. Dr. Onetto holds a Bachelor of Arts from the Academy of Paris (France), a Masters of Science in Pharmacology from the University of Montreal (Canada), a Doctor of Medicine degree from the University of Paris (France) and is qualified in pediatrics and hematology/oncology.
|
 |
Suzanne M. Shema, J.D.
Senior Vice President and General Counsel
Law and Compliance
Ms. Shema has served as our Senior Vice
President, Law and Compliance since April
2003. Previously, Ms. Shema served as Vice
President, Intellectual Property and Legal
Affairs from December 2001 to April 2003
and Senior Director, Intellectual Property
from May 2001 to December 2001. From February
2000 to May 2001, Ms. Shema served as General
Counsel at aQuantive, Inc., an internet
advertising company. From July 1998 to February
2000, Ms. Shema served as corporate counsel
at ZymoGenetics. From 1991 to March 1998,
she served as Associate General Counsel
at Research Corporation Technologies, Inc.,
a technology management company. From 1989
to 1991, Ms. Shema served as Associate General
Counsel at NeoRx Corporation, a biotechnology
company. From 1985 to 1988, she served as
an associate at the law firm of Seed and
Berry. Ms. Shema received a B.S. in Chemistry
from the University of Texas, an M.S. in
Chemistry from the University of Washington
and a J.D. from the University of Washington
School of Law. |
 |
Douglas E. Williams, Ph.D.
President and Chief Scientific Officer
Dr. Williams joined ZymoGenetics in 2004
as Chief Scientific Officer and Executive
Vice President and is responsible for the
company's research and development programs.
Dr. Williams has held senior level positions
at a number of notable biotechnology companies,
including Seattle Genetics, Immunex, Amgen
and Genesis Research and Development, a
New Zealand based biotechnology company.
As Executive Vice President and Chief Technology
Officer at Immunex, Dr. Williams played
a significant role in the discovery and
early development of Enbrel, the first biologic
approved for the treatment of rheumatoid
arthritis. In addition, Dr. Williams was
a member of Immunex Corporation's Board
of Directors. Before entering the biotechnology
industry, Dr. Williams served on the faculty
of the Indiana University School of Medicine
and worked in the Department of Laboratory
Medicine at the Roswell Park Memorial Institute.
Dr. Williams earned a B.S. magna cum laude
in Biological Sciences from the University
of Massachusetts, Lowell and a Ph.D. in
Physiology from the State University of
New York at Buffalo. |
|
|
|
Back to top
